MCID: MYS003
MIFTS: 67

Myasthenia Gravis

Categories: Rare diseases, Neuronal diseases, Immune diseases

Aliases & Classifications for Myasthenia Gravis

MalaCards integrated aliases for Myasthenia Gravis:

Name: Myasthenia Gravis 38 12 50 25 51 56 29 52 41 42 14 69
Autoimmune Myasthenia Gravis 56
Acquired Myasthenia 56
Mg 25

Characteristics:

Orphanet epidemiological data:

56
myasthenia gravis
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Europe),1-5/10000 (Europe),1-9/100000 (Worldwide),1-9/1000000 (United States),1-5/10000 (Canada),1-9/100000 (Spain),1-5/10000 (United Kingdom),1-9/100000 (United Kingdom),1-9/100000 (Serbia),1-5/10000 (United States),1-5/10000 (Serbia),1-9/100000 (Italy),1-5/10000 (Austria),1-9/100000 (Australia),1-5/10000 (Italy),1-9/100000 (Taiwan, Province of China),1-5/10000 (Australia),1-9/1000000 (Greece),1-5/10000 (Taiwan, Province of China),1-9/1000000 (Croatia),1-9/100000 (Estonia),1-9/100000 (Greece),1-9/100000 (Croatia),1-9/100000 (Egypt),1-9/1000000 (Worldwide); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 56  
Rare neurological diseases


Summaries for Myasthenia Gravis

NINDS : 51 Myasthenia gravis is a chronic autoimmune neuromuscular disease characterized by varying degrees of weakness of the skeletal muscles of the body, which are responsble for breathing and moving parts of the body. In myasthenia gravis, the immune system--which normally protects the body from foreign organisms--mistakenly attacks itself.  Symptoms vary in type and intensity. The hallmark of myasthenia gravis is muscle weakness that increases during periods of activity and improves after periods of rest. Certain muscles that control eye and eyelid movements, facial expression, chewing, talking, and swallowing are often, but not always, involved. The muscles that control breathing and neck and limb movements may also be affected. Myasthenia gravis is caused by a defect in the transmission of nerve impulses to muscles. Normally when impulses travel down the nerve, the nerve endings release a neurotransmitter substance called acetylcholine. In myasthenia gravis, antibodies produced by the body's own immune system block, alter, or destroy the receptors for acetylcholine. The first noticeable symptoms of myasthenia gravis may be weakness of the eye muscles, difficulty in swallowing, or slurred speech. Other symptoms may include blurred or double vision, drooping eyelid(s), and weakness in the arms, hands, fingers, legs, and neck. Myasthenia gravis is not directly inherited nor is it contagious.

MalaCards based summary : Myasthenia Gravis, also known as autoimmune myasthenia gravis, is related to dysphagia and autoimmune polyglandular syndrome type 3, and has symptoms including dysphagia, dysarthria and diplopia. An important gene associated with Myasthenia Gravis is AKAP12 (A-Kinase Anchoring Protein 12), and among its related pathways/superpathways are Allograft rejection and Immune response NFAT in immune response. The drugs Azathioprine and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include eye, thymus and skeletal muscle, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and behavior/neurological

NIH Rare Diseases : 50 myasthenia gravis (mg) is a chronic autoimmune neuromuscular disease characterized by weakness of the skeletal muscles. common symptoms include weakness of the muscles that control the eye and eyelid, facial expressions, chewing, talking, and swallowing. weakness tends to increase during periods of activity and improve after periods of rest. the condition results from a defect in the transmission of nerve impulses to muscles, which is due to the presence of antibodies against acetylcholine. the exact reason this occurs is not known. some cases have been linked to tumors in the thymus gland. researchers believe that variations in certain genes may increase a person's risk to develop mg, but other factors likely also play a role. there is no cure for mg at this time, but treatment can significantly improve muscle weakness. some cases may go into remission temporarily, and muscle weakness may disappear so that medications can be discontinued. last updated: 2/23/2017

MedlinePlus : 41 myasthenia gravis is a disease that causes weakness in your voluntary muscles. these are the muscles that you control. for example, you may have weakness in the muscles for eye movement, facial expressions, and swallowing. you can also have weakness in other muscles. this weakness gets worse with activity, and better with rest. myasthenia gravis is an autoimmune disease. your body's immune system makes antibodies that block or change some of the nerve signals to your muscles. this makes your muscles weaker. other conditions can cause muscle weakness, so myasthenia gravis can be hard to diagnose. tests used to make a diagnosis include blood, nerve, muscle, and imaging tests. with treatment, the muscle weakness often gets much better. medicines can help improve nerve-to-muscle messages and make muscles stronger. other drugs keep your body from making so many abnormal antibodies. these medicines can have major side effects, so they should be used carefully. there are also treatments which filter abnormal antibodies from the blood or add healthy antibodies from donated blood. sometimes, surgery to take out the thymus gland helps. some people with myasthenia gravis go into remission. this means that they do not have symptoms. the remission is usually temporary, but sometimes it can be permanent. nih: national institute of neurological disorders and stroke

Genetics Home Reference : 25 Myasthenia gravis is a disorder that causes weakness of the skeletal muscles, which are muscles that the body uses for movement. The weakness most often starts in the muscles around the eyes, causing drooping of the eyelids (ptosis) and difficulty coordinating eye movements, which results in blurred or double vision. In a form of the disorder called ocular myasthenia, the weakness remains confined to the eye muscles. In most people with myasthenia gravis, however, additional muscles in the face and neck are affected. Affected individuals may have unusual facial expressions, difficulty holding up the head, speech impairment (dysarthria), and chewing and swallowing problems (dysphagia) that may lead to choking, gagging, or drooling.

Wikipedia : 72 Myasthenia gravis (MG) is a long-term neuromuscular disease that leads to varying degrees of skeletal... more...

Related Diseases for Myasthenia Gravis

Diseases in the Myasthenia Gravis family:

Myasthenia Gravis Congenital Juvenile Myasthenia Gravis
Adult-Onset Myasthenia Gravis

Diseases related to Myasthenia Gravis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 475)
id Related Disease Score Top Affiliating Genes
1 dysphagia 32.8 IFNG IL10 TNF
2 autoimmune polyglandular syndrome type 3 32.7 IFNG IL2 TNF
3 myelitis 30.4 IFNG IL10 IL2
4 scabies 30.0 IFNG IL10 TNF
5 churg-strauss syndrome 29.6 IFNG IL10 IL4 TNF
6 systemic lupus erythematosus 28.4 CTLA4 IFNG IL10 IL2 IL4 TNF
7 lymphoma 28.0 CTLA4 IFNG IL10 IL2 IL4 MUSK
8 rheumatoid arthritis 27.8 CTLA4 IFNG IL10 IL2 IL4 TNF
9 juvenile myasthenia gravis 12.4
10 transient neonatal myasthenia gravis 12.3
11 adult-onset myasthenia gravis 12.3
12 neonatal myasthenia gravis 12.2
13 rippling muscle disease with myasthenia gravis 12.2
14 myasthenia gravis with thymus hyperplasia 12.2
15 myasthenia gravis congenital 12.1
16 myasthenia gravis, limb-girdle 12.0
17 congenital myasthenic syndrome 11.8
18 thymoma 11.6
19 neuromuscular disease 11.6
20 rippling muscle disease 11.4
21 paraneoplastic syndromes 11.4
22 autoimmune oophoritis 11.3
23 myasthenic syndrome, congenital, 6, presynaptic 11.2
24 proximal spinal muscular atrophy 11.0
25 swallowing disorders 11.0
26 escobar syndrome 11.0
27 thyrotoxic periodic paralysis 11.0
28 thymus cancer 11.0
29 paraneoplastic neurologic disorders 11.0
30 congenital nephrotic syndrome finnish type 11.0 CHRNE MUSK
31 multiple pterygium syndrome, lethal type 10.8 CHRNA1 CHRNE
32 pure autonomic failure 10.8 IL10 TNF
33 dystonia 2 10.7 MUSK RAPSN
34 renal hypodysplasia 10.7 MUSK RAPSN
35 scirrhous adenocarcinoma 10.7 IL2 TNF
36 multiple familial trichoepithelioma 10.6 IL10 TNF
37 sternal cleft 10.6 IFNG TNF
38 myoclonic astatic epilepsy 10.5 IFNG IL4
39 moderately severe hemophilia b 10.5 CTLA4 IL10 TNF
40 hepadnavirus infection 10.5 IFNG IL10 TNF
41 senile reticular retinal degeneration 10.5 IFNG IL10 TNF
42 small cell lung cancer, adult 10.5 CHRNA1 CHRNE
43 conduct disorder 10.5 IFNG IL10 TNF
44 bartonellosis 10.5 IFNG IL10 TNF
45 bulbospinal polio 10.5 IFNG IL2
46 3p- syndrome 10.5 CHRNA1 CHRNE CHRNG RYR1
47 disease of mental health 10.5 IFNG IL10 TNF
48 extrahepatic bile duct adenocarcinoma 10.5 IFNG IL10 TNF
49 type 1 papillary adenoma of the kidney 10.5 IL10 TNF
50 melioidosis 10.4 IFNG IL10 TNF

Graphical network of the top 20 diseases related to Myasthenia Gravis:



Diseases related to Myasthenia Gravis

Symptoms & Phenotypes for Myasthenia Gravis

Human phenotypes related to Myasthenia Gravis:

56 32 (show all 28)
id Description HPO Frequency Orphanet Frequency HPO Source Accession
1 dysphagia 56 32 frequent (33%) Frequent (79-30%) HP:0002015
2 dysarthria 56 32 frequent (33%) Frequent (79-30%) HP:0001260
3 diplopia 56 32 frequent (33%) Frequent (79-30%) HP:0000651
4 seizures 56 32 very rare (1%) Very rare (<4-1%) HP:0001250
5 ptosis 56 32 frequent (33%) Frequent (79-30%) HP:0000508
6 psychosis 56 32 very rare (1%) Very rare (<4-1%) HP:0000709
7 hemolytic anemia 56 32 very rare (1%) Very rare (<4-1%) HP:0001878
8 systemic lupus erythematosus 56 32 occasional (7.5%) Occasional (29-5%) HP:0002725
9 dyspnea 56 32 frequent (33%) Frequent (79-30%) HP:0002094
10 hyperthyroidism 56 32 occasional (7.5%) Occasional (29-5%) HP:0000836
11 ophthalmoparesis 56 32 frequent (33%) Frequent (79-30%) HP:0000597
12 hashimoto thyroiditis 56 32 occasional (7.5%) Occasional (29-5%) HP:0000872
13 acrocyanosis 56 32 very rare (1%) Very rare (<4-1%) HP:0001063
14 glycosuria 56 32 occasional (7.5%) Occasional (29-5%) HP:0003076
15 hearing impairment 56 32 occasional (7.5%) Occasional (29-5%) HP:0000365
16 hyperacusis 56 32 occasional (7.5%) Occasional (29-5%) HP:0010780
17 bulbar palsy 56 32 frequent (33%) Frequent (79-30%) HP:0001283
18 paresthesia 56 32 occasional (7.5%) Occasional (29-5%) HP:0003401
19 rheumatoid arthritis 56 32 occasional (7.5%) Occasional (29-5%) HP:0001370
20 primary adrenal insufficiency 56 32 occasional (7.5%) Occasional (29-5%) HP:0008207
21 hepatitis 56 32 very rare (1%) Very rare (<4-1%) HP:0012115
22 myositis 56 32 frequent (33%) Frequent (79-30%) HP:0100614
23 abnormality of the thymus 56 32 frequent (33%) Frequent (79-30%) HP:0000777
24 single fiber emg abnormality 56 32 frequent (33%) Frequent (79-30%) HP:0030006
25 acetylcholine receptor antibody positivity 56 32 frequent (33%) Frequent (79-30%) HP:0030208
26 muscle specific kinase antibody positivity 56 32 frequent (33%) Frequent (79-30%) HP:0030210
27 pure red cell aplasia 56 32 very rare (1%) Very rare (<4-1%) HP:0012410
28 muscle weakness 56 Very frequent (99-80%)

UMLS symptoms related to Myasthenia Gravis:


back pain, headache, pain, sciatica, seizures, syncope, tremor, chronic pain, muscle weakness, facial paresis, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.17 TMPO
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-141 9.17 TMPO
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-155 9.17 CHRNA1 RAPSN TMPO
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-193 9.17 TMPO
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 9.17 TMPO

MGI Mouse Phenotypes related to Myasthenia Gravis:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.38 ACHE AGRN AKAP12 CHRNA1 CHRNE CHRNG
2 growth/size/body region MP:0005378 10.31 ACHE AGRN CHRNE CHRNG IFNG IL10
3 homeostasis/metabolism MP:0005376 10.3 ACHE AGRN CHRNG CTLA4 IFNG IL10
4 mortality/aging MP:0010768 10.3 TTN ACHE AGRN AKAP12 CHRNA1 CHRNE
5 hematopoietic system MP:0005397 10.22 ACHE AKAP12 CTLA4 IFNG IL10 IL2
6 digestive/alimentary MP:0005381 10.11 CTLA4 IFNG IL10 IL2 IL4 RYR1
7 muscle MP:0005369 10.1 ACHE AGRN AKAP12 CHRNE CHRNG IFNG
8 integument MP:0010771 10.09 CTLA4 IFNG IL10 IL4 MUSK RYR1
9 craniofacial MP:0005382 10.07 IFNG IL10 IL4 RYR1 TNF TTN
10 nervous system MP:0003631 10.07 ACHE AGRN AKAP12 CHRNA1 CHRNE CHRNG
11 respiratory system MP:0005388 10 TNF ACHE AGRN AKAP12 CHRNE CHRNG
12 liver/biliary system MP:0005370 9.95 TNF AKAP12 CTLA4 IFNG IL10 IL2
13 skeleton MP:0005390 9.61 CHRNA1 CTLA4 IFNG IL10 IL4 MUSK
14 vision/eye MP:0005391 9.23 ACHE IFNG IL10 IL2 IL4 MBP

Drugs & Therapeutics for Myasthenia Gravis

Drugs for Myasthenia Gravis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4,Phase 3 446-86-6 2265
2
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
3 glucocorticoids Phase 4,Phase 3
4 Hormone Antagonists Phase 4,Phase 3
5 Hormones Phase 4,Phase 3
6 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3
7 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Early Phase 1
8 Antimetabolites Phase 4,Phase 3,Phase 2
9 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2
10 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
11 Rho(D) Immune Globulin Phase 4,Phase 3,Phase 2
12 gamma-Globulins Phase 4,Phase 3,Phase 2
13 Immunoglobulins Phase 4,Phase 3,Phase 2
14 Immunoglobulins, Intravenous Phase 4,Phase 3,Phase 2
15 Anti-Inflammatory Agents Phase 4,Phase 3
16 Antibodies Phase 4,Phase 3,Phase 2
17 Antineoplastic Agents, Hormonal Phase 4,Phase 3
18
Mycophenolic acid Approved Phase 3 24280-93-1 446541
19
Mycophenolate mofetil Approved, Investigational Phase 3 128794-94-5 5281078
20
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
21
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
22
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492
23
Rocuronium Approved Phase 3 119302-91-9, 143558-00-3 441290
24
rituximab Approved Phase 3,Phase 1,Phase 2 174722-31-7 10201696
25
4-Aminopyridine Approved Phase 3 504-24-5 1727
26
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
27
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
28
Guaifenesin Approved, Vet_approved Phase 3 93-14-1 3516
29
Aluminum hydroxide Approved Phase 2, Phase 3,Phase 1 21645-51-2
30 tannic acid Approved, Nutraceutical Phase 3
31 Pyridostigmine Bromide Phase 3 101-26-8
32 Cholinergic Agents Phase 3,Phase 1,Phase 2
33 Cholinesterase Inhibitors Phase 3
34 Neurotransmitter Agents Phase 3,Phase 1,Phase 2
35 Anti-Bacterial Agents Phase 3
36 Antibiotics, Antitubercular Phase 3
37 Prednisolone acetate Phase 3
38 3,4-diaminopyridine Phase 3
39 Methylprednisolone acetate Phase 3
40 Methylprednisolone Hemisuccinate Phase 3
41 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
42 Neuromuscular Agents Phase 3
43 Neuromuscular Blocking Agents Phase 3
44 Neuromuscular Nondepolarizing Agents Phase 3
45 Vaccines Phase 3,Phase 1,Phase 2
46 Peripheral Nervous System Agents Phase 3
47 Potassium Channel Blockers Phase 3
48 Prednisolone hemisuccinate Phase 3
49 Prednisolone phosphate Phase 3
50 Bromides Phase 3

Interventional clinical trials:

(show top 50) (show all 72)

id Name Status NCT ID Phase Drugs
1 Study Comparing Two Tapering Strategies of Prednisone in Myasthenia Gravis Completed NCT00987116 Phase 4 Prednisone - Azathioprine
2 Intravenous Immunoglobulin and Plasma Exchange in Myasthenia Gravis Completed NCT01179893 Phase 4
3 The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy Unknown status NCT01727193 Phase 3 Azathioprine;Leflunomide
4 Intravenous Immune Globulin Treatment Compared to Placebo in Patients With Myasthenia Gravis Completed NCT00306033 Phase 3 Intravenous ImmuneGlobulin
5 Mycophenolate Mofetil in Myasthenia Gravis Completed NCT00285350 Phase 3 mycophenolate mofetil
6 Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy Completed NCT00294658 Phase 3 prednisone alone
7 Efficacy and Safety Study of GB-0998 for Treatment of Generalized Myasthenia Gravis Completed NCT00515450 Phase 3
8 A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis Completed NCT01325571 Phase 3 Tacrolimus capsule;Placebo
9 Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) Completed NCT01997229 Phase 3 Placebo
10 FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients Completed NCT00309088 Phase 3 tacrolimus;placebo
11 A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis. Completed NCT00408213 Phase 3 mycophenolate mofetil [CellCept];Placebo
12 A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis Completed NCT00683969 Phase 3 mycophenolate mofetil (CellCept);placebo
13 An Open Study for Steroid Resistant, Non-Thymectomized MG Patients Completed NCT00309101 Phase 3 tacrolimus
14 A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS) Completed NCT01377922 Phase 3 Amifampridine Phosphate;Placebo
15 Skeletal Muscle Paralysis in Hypothermic Patients After Cardiac Arrest Completed NCT01719770 Phase 3 rocuronium
16 A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia Gravis Recruiting NCT02950155 Phase 3 Rituximab;Sodium Chloride solution
17 A Study to Evaluate the Efficacy of CV-MG01 (Myasterix) in Myasthenia Gravis Recruiting NCT03165435 Phase 2, Phase 3
18 A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations Recruiting NCT02413580 Phase 3
19 A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) Recruiting NCT02774239 Phase 3 Human normal immunoglobulin G (IgG)
20 Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS) Recruiting NCT02970162 Phase 3 Amifampridine Phosphate;Placebo Oral Tablet
21 ECU-MG-302: An Extension Trial of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis Active, not recruiting NCT02301624 Phase 3
22 Study to Evaluate Amifampridine Phosphate in Patients With MuSK-MG Not yet recruiting NCT03304054 Phase 3 Amifampridine Phosphate;Placebo Oral Tablet
23 Efficacy of Prednisone In the Treatment of Ocular Myasthenia Terminated NCT00995722 Phase 3 Prednisone;Placebo
24 Sulfamethoxazole for the Treatment of Primary PREPL Deficiency Unknown status NCT02640443 Phase 2 Sulfamethoxazole
25 Efficacy of Methotrexate in Myasthenia Gravis Completed NCT00814138 Phase 2 Methotrexate
26 A Pilot Trial of Rituxan in Refractory Myasthenia Gravis Completed NCT00619671 Phase 1, Phase 2 Rituximab (Rituxan)
27 Rituximab for the Treatment of Refractory Inflammatory Myopathies and Refractory Myasthenia Gravis Completed NCT00774462 Phase 2 Rituximab
28 The Evaluation of Belimumab in Myasthenia Gravis (MG) Completed NCT01480596 Phase 2
29 Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis. Recruiting NCT03052751 Phase 2 UCB7665
30 Safety,Tolerability,Pharmacokinetics and Efficacy of CFZ533 in Moderate to Severe Myasthenia Gravis Recruiting NCT02565576 Phase 2 Placebo;CFZ533
31 Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis Recruiting NCT02100969 Phase 2 HIZENTRA ®
32 A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness Recruiting NCT02965573 Phase 2 Placebo
33 Efficacy and Safety of IGIV-C in Corticosteroid Dependent Patients With Generalized Myasthenia Gravis Recruiting NCT02473965 Phase 2 IGIV-C;Placebo
34 A Study to Evaluate the Efficacy and Safety of IGIV-C in Symptomatic Subjects With Generalized Myasthenia Gravis Recruiting NCT02473952 Phase 2 IGIV-C;Placebo
35 The Safety and Efficacy of "3-Hole" Subxiphorid Approach in the Treatment of Anterior Mediastinal Tumor Recruiting NCT02317224 Phase 2
36 Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) Recruiting NCT02102594 Phase 2 Bortezomib
37 Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure Recruiting NCT03174964 Phase 2 IVIg
38 Immunomodulatory Effects of IVIg on Pregnancy Rate of Patient With Recurrent Pregnancy Loss Recruiting NCT03174951 Phase 2 IVIg
39 BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis Active, not recruiting NCT02110706 Phase 2 Rituximab;Placebo
40 Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis Active, not recruiting NCT02609022 Phase 1, Phase 2
41 Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis Terminated NCT00727194 Phase 2 eculizumab;Placebo
42 Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis Terminated NCT01268280 Phase 2 Placebo;250 mg CK-2017357;500 mg CK-2017357
43 Exercise for Stable Myasthenia Gravis Recruiting NCT01047761 Phase 1
44 Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis Terminated NCT00424489 Phase 1
45 A Pilot Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Generalized Myasthenia Gravis Unknown status NCT01555580 Early Phase 1 Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
46 Trial of Mycophenolic Acid Versus Azathioprine in the Treatment of Corticosteroid-refractory Myasthenia Gravis Unknown status NCT00997412 Mycophenolic acid;AZA
47 The Effect of Erythromycin on Occurrence of Leaks From Cervical Esophageal-Gastric Anastomosis After Trans-Hiatal Esophagectomy Unknown status NCT00373919 intravenous (IV) administration of erythromycin
48 Inherited Myokymia: A Clinical and Genetic Study of a Family Unknown status NCT01250704
49 Perception and Multisensory Integration in Neurological Patients Using fMRI Unknown status NCT01469858
50 Therapeutic Plasma Exchange in MG Completed NCT01927692

Search NIH Clinical Center for Myasthenia Gravis

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Myasthenia Gravis cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Myasthenia Gravis:
Hematopoietic stem cells for refractory myasthenia gravis
Embryonic/Adult Cultured Cells Related to Myasthenia Gravis:
Peripheral blood-derived hematopoietic stem cells

Cochrane evidence based reviews: myasthenia gravis

Genetic Tests for Myasthenia Gravis

Genetic tests related to Myasthenia Gravis:

id Genetic test Affiliating Genes
1 Myasthenia Gravis 29

Anatomical Context for Myasthenia Gravis

MalaCards organs/tissues related to Myasthenia Gravis:

39
Eye, Thymus, Skeletal Muscle, Testes, T Cells, B Cells, Thyroid

Publications for Myasthenia Gravis

Articles related to Myasthenia Gravis:

(show top 50) (show all 1474)
id Title Authors Year
1
Immature Exosomes Derived from MicroRNA-146a Overexpressing Dendritic Cells Act as Antigen-Specific Therapy for Myasthenia Gravis. ( 28523463 )
2017
2
Clinical features and evolution of juvenile myasthenia gravis in a French cohort. ( 28877546 )
2017
3
Early onset bilateral juvenile myasthenia gravis masquerading as simple congenital ptosis. ( 28293536 )
2017
4
The Role of Sugammadex in Symptomatic Transient Neonatal Myasthenia Gravis: A Case Report. ( 28691986 )
2017
5
CCR9 AND CCR7 are overexpressed in CD4(-) CD8(-) thymocytes of myasthenia gravis patients. ( 26616645 )
2017
6
Pure red cell aplasia and myasthenia gravis: a patient having both autoimmune conditions in the absence of thymoma. ( 28893803 )
2017
7
Analysis of mortality and related factors in 2195 adult myasthenia gravis patients in a 10-year follow-up study. ( 28488612 )
2017
8
Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis. ( 28921038 )
2017
9
Juvenile myasthenia gravis in Norway: Clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort. ( 28457757 )
2017
10
Acupuncture for Management of Type 2 Diabetes Mellitus in a Patient with Myasthenia Gravis: A Case Report. ( 28889846 )
2017
11
Transient neonatal myasthenia gravis due to a mother with ocular onset of anti-muscle specific kinase myasthenia gravis. ( 28495046 )
2017
12
Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis. ( 28878127 )
2017
13
Pediatric Myasthenia Gravis. ( 28941526 )
2017
14
Thymoma with immunodeficiency/Good syndrome associated with myasthenia gravis. ( 28450687 )
2017
15
HLA and age of onset in myasthenia gravis. ( 28495048 )
2017
16
Outcome after Robotic-Assisted Thymectomy in Children and Adolescents with Acetylcholine Receptor Antibody-Positive Juvenile Myasthenia Gravis. ( 28628938 )
2017
17
Obinutuzumab Plus Chlorambucil in a Patient with Severe Myasthenia Gravis and Chronic Lymphocytic Leukemia. ( 28869483 )
2017
18
Selective or predominant triceps muscle weakness in African-American patients with myasthenia gravis. ( 28495049 )
2017
19
Construction of an miRNA-regulated drug-pathway network reveals drug repurposing candidates for myasthenia gravis. ( 28075449 )
2017
20
Ocular Presentation of Myasthenia Gravis: A Natural History Cohort. ( 28881457 )
2017
21
Hickam's dictum: Myasthenia Gravis presenting concurrently with Graves' disease. ( 28882932 )
2017
22
GVHD-like erythroderma in the clinical course of thymoma-associated myasthenia gravis. ( 28524043 )
2017
23
Suppression of CHRN endocytosis by carbonic anhydrase CAR3 in the pathogenesis of myasthenia gravis. ( 28933591 )
2017
24
A possible role of low regulatory T cells in anti-acetylcholine receptor antibody positive myasthenia gravis after bone marrow transplantation. ( 28506261 )
2017
25
A quantitative method for the assessment of dysarthrophonia in myasthenia gravis. ( 28477705 )
2017
26
Diagnostic Utility of Repetitive Nerve Stimulation in a Large Cohort of Patients With Myasthenia Gravis. ( 28872522 )
2017
27
Thymectomy and myasthenia gravis: A history of surgical passion and scientific excellence. ( 28479053 )
2017
28
Juvenile myasthenia gravis. ( 28784230 )
2017
29
The association between scabies and myasthenia gravis: A nationwide population-based cohort study. ( 28890037 )
2017
30
Evaluation of coexisting polymyositis in feline myasthenia gravis: A case series. ( 28687435 )
2017
31
Stiff-person syndrome after thymectomy in myasthenia gravis mimicking a post-thymectomy myasthenic crisis. ( 28879920 )
2017
32
Clinical and pathological aspects of microscopic thymoma with myasthenia gravis and review of published reports. ( 28740673 )
2017
33
I^2-Adrenergic receptor gene polymorphisms in the relapse of myasthenia gravis with thymus abnormality. ( 27338803 )
2017
34
Specific removal of autoantibodies by extracorporeal immunoadsorption ameliorates experimental autoimmune myasthenia gravis. ( 28912035 )
2017
35
Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan. ( 28821685 )
2017
36
Pyridostigmine-Induced Bradycardia in Patient With MuSK-Ab-Positive Myasthenia Gravis and Alopecia Universalis. ( 28827491 )
2017
37
Randomized Trial of Thymectomy in Myasthenia Gravis. ( 28471717 )
2017
38
Safe Use of Atypical Antipsychotics in a Patient With Postpartum Psychosis and a History of Seronegative Myasthenia Gravis. ( 28703945 )
2017
39
Effect of ethnic origin and gender on the clinical manifestations of myasthenia gravis among the Jewish population in Israel. ( 28495138 )
2017
40
Screening for lipoprotein receptor-related protein 4-, agrin-, and titin-antibodies and exploring the autoimmune spectrum in myasthenia gravis. ( 28516329 )
2017
41
Profile of upregulated inflammatory proteins in sera of Myasthenia Gravis patients. ( 28045063 )
2017
42
Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing. ( 28087666 )
2017
43
Anesthetic Management of a Patient With Antimuscle-Specific Kinase Antibody-Positive Myasthenia Gravis Undergoing an Open Cholecystectomy: A Case Report. ( 28079665 )
2017
44
Tacrolimus in the treatment of myasthenia gravis in patients with an inadequate response to glucocorticoid therapy: randomized, double-blind, placebo-controlled study conducted in China. ( 28861121 )
2017
45
Autoimmune antibodies to collagen XIII in myasthenia gravis patients. ( 28885698 )
2017
46
Robotic thymectomy for myasthenia gravis with or without thymoma-surgical and neurological outcomes. ( 28084239 )
2017
47
Orbital mantle cell lymphoma presenting as myasthenia gravis. ( 28820310 )
2017
48
Myasthenia Gravis, Mediastinal Goiter, and Crohn's Disease. ( 28528037 )
2017
49
TNFAIP3 gene rs7749323 polymorphism is associated with late onset myasthenia gravis. ( 28514294 )
2017
50
Myasthenia Gravis and Its Aeromedical Implications. ( 28061919 )
2017

Variations for Myasthenia Gravis

Expression for Myasthenia Gravis

Search GEO for disease gene expression data for Myasthenia Gravis.

Pathways for Myasthenia Gravis

Pathways related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 33)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.81 CTLA4 IFNG IL10 IL2 IL4 TNF
2
Show member pathways
12.6 IFNG IL10 IL2 IL4 TNF
3
Show member pathways
12.55 IFNG IL10 IL2 IL4 TNF
4
Show member pathways
12.37 CTLA4 IFNG IL10 IL2 IL4 TNF
5 12.3 CTLA4 IFNG IL10 IL2 IL4 TNF
6
Show member pathways
12.22 IFNG IL10 IL4 TNF
7
Show member pathways
12.18 IFNG IL10 IL2 IL4
8
Show member pathways
12.12 IFNG IL10 IL2 IL4 TNF
9 11.92 IFNG IL10 IL2 IL4 TNF
10
Show member pathways
11.91 IFNG IL10 IL2 TNF
11 11.83 CTLA4 IFNG TNF TNFSF13B
12 11.75 IFNG IL2 IL4
13 11.75 IFNG IL10 IL2 TNF
14 11.67 IFNG IL10 IL2 IL4 TNF
15
Show member pathways
11.63 IFNG IL2 TNF
16
Show member pathways
11.61 IFNG IL2 TNF
17 11.6 AGRN CHRNA1 MUSK RAPSN
18
Show member pathways
11.6 CTLA4 IFNG IL2 IL4 TNF
19 11.52 IFNG IL2 TNF
20 11.51 IFNG IL2 IL4 MBP TNF TNFSF13B
21 11.49 IL10 IL4 TNF
22 11.49 IFNG IL10 TNF
23 11.47 IFNG IL2 TNF
24 11.47 IFNG IL10 IL2 IL4
25 11.4 CTLA4 IL10 IL4 TNF TNFSF13B
26
Show member pathways
11.34 IFNG IL10 IL2 TNF
27 11.33 IFNG IL10 TNF
28 11.29 IFNG IL2 IL4
29 11.27 IFNG IL4 TNF
30 11.19 IL10 IL2 IL4 TNF TNFSF13B
31 11.12 IFNG IL10 IL2 IL4
32 10.79 CHRNA1 CHRNE RYR1
33 10.5 IFNG IL10 IL2 IL4 TNF

GO Terms for Myasthenia Gravis

Cellular components related to Myasthenia Gravis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cell junction GO:0030054 9.87 ACHE AGRN CHRNA1 CHRNE CHRNG MUSK
2 external side of plasma membrane GO:0009897 9.73 CTLA4 IFNG IL4 TNF
3 postsynaptic membrane GO:0045211 9.65 CHRNA1 CHRNE CHRNG MUSK RAPSN
4 acetylcholine-gated channel complex GO:0005892 9.33 CHRNA1 CHRNE CHRNG
5 neuromuscular junction GO:0031594 9.26 ACHE CHRNA1 MUSK RAPSN
6 synapse GO:0045202 9.17 ACHE AGRN CHRNA1 CHRNE CHRNG MUSK
7 plasma membrane GO:0005886 10.18 ACHE AGRN AKAP12 CHRNA1 CHRNE CHRNG
8 extracellular region GO:0005576 10.06 ACHE AGRN IFNG IL10 IL2 IL4

Biological processes related to Myasthenia Gravis according to GeneCards Suite gene sharing:

(show all 29)
id Name GO ID Score Top Affiliating Genes
1 excitatory postsynaptic potential GO:0060079 9.81 CHRNA1 CHRNE CHRNG
2 muscle contraction GO:0006936 9.81 CHRNE CHRNG RYR1 TTN
3 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.8 IFNG IL2 IL4
4 regulation of postsynaptic membrane potential GO:0060078 9.77 CHRNA1 CHRNE CHRNG
5 response to nicotine GO:0035094 9.77 CHRNA1 CHRNE CHRNG
6 positive regulation of protein phosphorylation GO:0001934 9.77 IFNG IL2 IL4 MUSK TNF
7 positive regulation of B cell proliferation GO:0030890 9.76 IL2 IL4 TNFSF13B
8 positive regulation of T cell proliferation GO:0042102 9.71 IFNG IL2 IL4 TNFSF13B
9 neuromuscular synaptic transmission GO:0007274 9.67 CHRNA1 CHRNE CHRNG
10 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.64 IL10 TNF
11 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.64 IL10 MBP
12 skeletal muscle acetylcholine-gated channel clustering GO:0071340 9.63 MUSK RAPSN
13 defense response to protozoan GO:0042832 9.63 IFNG IL10 IL4
14 endothelial cell apoptotic process GO:0072577 9.62 IL10 TNF
15 negative regulation of cytokine secretion involved in immune response GO:0002740 9.61 IL10 TNF
16 type 2 immune response GO:0042092 9.61 IL10 IL4
17 negative regulation of growth of symbiont in host GO:0044130 9.61 IFNG IL10 TNF
18 negative regulation of T-helper 17 cell differentiation GO:2000320 9.58 IL2 IL4
19 regulation of isotype switching GO:0045191 9.57 IL10 IL4
20 positive regulation of mononuclear cell migration GO:0071677 9.56 IL4 TNF
21 B cell costimulation GO:0031296 9.55 IL4 TNFSF13B
22 receptor biosynthetic process GO:0032800 9.54 IL10 TNF
23 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.52 IFNG TNF
24 positive regulation of isotype switching to IgG isotypes GO:0048304 9.5 IFNG IL2 IL4
25 positive regulation of vitamin D biosynthetic process GO:0060557 9.48 IFNG TNF
26 positive regulation of chemokine biosynthetic process GO:0045080 9.43 IFNG IL4 TNF
27 positive regulation of MHC class II biosynthetic process GO:0045348 9.33 IFNG IL10 IL4
28 synaptic transmission, cholinergic GO:0007271 9.26 CHRNA1 CHRNE CHRNG RAPSN
29 immune response GO:0006955 9.23 CTLA4 IFNG IL10 IL2 IL4 MBP

Molecular functions related to Myasthenia Gravis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protease binding GO:0002020 9.62 MBP RYR1 TNF TTN
2 extracellular ligand-gated ion channel activity GO:0005230 9.58 CHRNA1 CHRNE CHRNG
3 ligand-gated ion channel activity GO:0015276 9.54 CHRNA1 CHRNE CHRNG
4 acetylcholine-gated cation-selective channel activity GO:0022848 9.43 CHRNA1 CHRNE CHRNG
5 cytokine activity GO:0005125 9.43 IFNG IL10 IL2 IL4 TNF TNFSF13B
6 acetylcholine receptor activity GO:0015464 9.33 CHRNA1 CHRNE CHRNG
7 acetylcholine binding GO:0042166 8.92 ACHE CHRNA1 CHRNE CHRNG

Sources for Myasthenia Gravis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....